<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="266">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00916409</url>
  </required_header>
  <id_info>
    <org_study_id>EF-14</org_study_id>
    <nct_id>NCT00916409</nct_id>
  </id_info>
  <brief_title>Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovoCure Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy
      and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of
      care in the treatment of newly diagnosed GBM patients. The device is an experimental,
      portable, battery operated device for chronic administration of alternating electric fields
      (termed TTFields or TTF) to the region of the malignant tumor, by means of surface,
      insulated electrode arrays.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAST CLINICAL EXPERIENCE:

      The effect of the electric fields generated by the NovoTTF-100A device (TTFields, TTF) has
      been tested in a large prospective, randomized trial, in recurrent GBM. The outcome of
      subjects treated with the NovoTTF-100A device was compared to those treated with an
      effective best standard of care chemotherapy (including bevacizumab). NovoTTF-100A subjects
      had comparable overall survival to subjects receiving the best available chemotherapy in the
      US today. Similar results showing comparability of NovoTTF-100A to BSC chemotherapy were
      seen in all secondary endpoints.

      Recurrent GBM patients treated with the NovoTTF-100A device in this trial experienced fewer
      side effects in general, significantly fewer treatment related side effects, and
      significantly lower gastrointestinal, hematological and infectious adverse events compared
      to controls. The only device-related adverse events seen were a mild to moderate skin
      irritation beneath the device electrodes. Finally, quality of life measures were better in
      NovoTTF-100A subjects as a group when compared to subjects receiving effective best standard
      of care chemotherapy.

      In a small scale pilot trial in newly diagnosed GBM patients, the treatment was well
      tolerated and suggested that NovoTTF-100A may improve time to disease progression and
      overall survival of newly diagnosed GBM patients. Although the number of patients in the
      pilot trial was small, The FDA has determined that the data gathered so far warrant testing
      of NovoTTF-100A treatment as a possible therapy for patients with newly diagnosed GBM.

      DESCRIPTION OF THE TRIAL:

      All patients included in this trial are newly diagnosed GBM patients who underwent a biopsy
      or surgery (with or without Gliadel wafers), followed by radiation therapy in combination
      with Temozolomide chemotherapy. In addition, all patients must meet all eligibility
      criteria.

      Eligible patients will be randomly assigned to one of two groups:

        1. Treatment with the NovoTTF-100A device in combination with Temozolomide chemotherapy.

        2. Treatment with Temozolomide alone, as the best known standard of care.

      Patients will be randomized at a 2:1 ratio (2 of every three patients who participate in the
      trial will be treated with the NovoTTF-100A device). Baseline tests will be performed in
      patients enrolled in both arms, including specific genetic tests done using tumor samples
      obtained during their initial surgery. If assigned to the NovoTTF-100A in combination with
      Temozolomide group, the patients will be treated continuously with the device until second
      progression. They will also receive temozolomide and possibly a second line treatment that
      can be one of the following: re-operation, local radiotherapy (gamma-knife), a second line
      of chemotherapy or a combination of the above.

      NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays
      on the head. Electrode array placement will require shaving of the scalp before and
      frequently during the treatment. After an initial short visit to the clinic for training and
      monitoring, patients will be released to continue treatment at home where they can maintain
      their regular daily routine.

      During the trial, regardless of which treatment group the patient was assigned to, he or she
      will need to return once every month to the clinic where an examination by a physician and a
      routine laboratory examinations will be done. These routine visits will continue for as long
      as the patient's disease is not progressing for the second time under the study treatment.
      If such occurs, patients will need to return once per month for two more months to the
      clinic for similar follow up examinations.

      During the visits to the clinic patients will be examined physically and neurologically.
      Additionally, routine blood tests will be performed. A routine MRI of the head will be
      performed at baseline and every second month thereafter, until second progression. After
      this follow up plan, patients will be contacted once per month by telephone to answer basic
      questions about their health status.

      SCIENTIFIC BACKGROUND:

      Electric fields exert forces on electric charges similar to the way a magnet exerts forces
      on metallic particles within a magnetic field. These forces cause movement and rotation of
      electrically charged biological building blocks, much like the alignment of metallic
      particles seen along the lines of force radiating outwards from a magnet.

      Electric fields can also cause muscles to twitch and if strong enough may heat tissues.
      TTFields are alternating electric fields of low intensity. This means that they change their
      direction repetitively many times a second. Since they change direction very rapidly (200
      thousand times a second), they do not cause muscles to twitch, nor do they have any effects
      on other electrically activated tissues in the body (brain, nerves and heart). Since the
      intensities of TTFields in the body are very low, they do not cause heating.

      The breakthrough finding made by NovoCure was that finely tuned alternating fields of very
      low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in
      the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are
      multiplying, TTFields cause the building blocks of these cells to move and pile up in such a
      way that the cells physically explode. In addition, cancer cells also contain miniature
      building blocks which act as tiny motors in moving essential parts of the cells from place
      to place. TTFields cause these tiny motors to fall apart since they have a special type of
      electric charge.

      As a result of these two effects, cancer tumor growth is slowed and can even reverse after
      continuous exposure to TTFields.

      Other cells in the body (normal healthy tissues) are affected much less than cancer cells
      since they multiply at a much slower rate if at all. In addition TTFields can be directed to
      a certain part of the body, leaving sensitive areas out of their reach.

      In conclusion, TTField hold the promise of serving as a brand new cancer treatment with very
      few side effects and promising affectivity in slowing or reversing this disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) time</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>NovoTTF-100A device in combination with Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temozolomide alone, as the best known standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with Temozolomide, as the best known standard of care for Glioblastoma Multiforme patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-100A device</intervention_name>
    <description>patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.</description>
    <arm_group_label>NovoTTF-100A device in combination with Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.
Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles.</description>
    <arm_group_label>Temozolomide alone, as the best known standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathological evidence of GBM using WHO classification criteria.

          2. &gt; 18 years of age.

          3. Received maximal debulking surgery and radiotherapy concomitant with Temozolomide
             (45-70Gy):

               1. Patients may enroll in the study if received Gliadel wafers before entering the
                  trial

               2. Any additional treatments received prior to enrollment will be considered an
                  exclusion.

               3. Minimal dose for concomitant radiotherapy is 45 Gy

          4. Karnofsky scale ≥ 70

          5. Life expectancy at least 3 months

          6. Participants of childbearing age must use effective contraception.

          7. All patients must sign written informed consent.

          8. Treatment start date at least 4 weeks out from surgery.

          9. Treatment start date at least 4 weeks out but not more than 7 weeks from the later of
             last dose of concomitant Temozolomide or radiotherapy.

        Exclusion Criteria:

          1. Progressive disease (according to MacDonald Criteria). If pseudoprogression is
             suspected, additional imaging studies must be performed to rule out true progression.

          2. Actively participating in another clinical treatment trial

          3. Pregnant

          4. Significant co-morbidities at baseline which would prevent maintenance Temozolomide
             treatment:

               1. Thrombocytopenia (platelet count &lt; 100 x 103/μL)

               2. Neutropenia (absolute neutrophil count &lt; 1.5 x 103/μL)

               3. CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)

               4. Significant liver function impairment - AST or ALT &gt; 3 times the upper limit of
                  normal

               5. Total bilirubin &gt; upper limit of normal

               6. Significant renal impairment (serum creatinine &gt; 1.7 mg/dL)

          5. Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other
             implanted electronic devices in the brain, or documented clinically significant
             arrhythmias.

          6. Infra-tentorial tumor

          7. Evidence of increased intracranial pressure (midline shift &gt; 5mm, clinically
             significant papilledema, vomiting and nausea or reduced level of consciousness)

          8. History of hypersensitivity reaction to Temozolomide or a history of hypersensitivity
             to DTIC.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Stupp, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Lausanne Hospital - Multidisciplinary Oncology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip H. Gutin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric T. Wong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herbert H. Engelhard, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manfred Westphal, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghazala Kabani</last_name>
    <email>patientinfo@novocure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiru Pillay, RN</last_name>
      <phone>205-934-1842</phone>
      <email>tpillay@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hassan Fathallah-Shaykh, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrow Neurology Clinics</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Ralph</last_name>
      <phone>602-406-6275</phone>
      <email>andrea.ralph@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Lynn S Ashby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Ching</last_name>
      <phone>626-471-9393</phone>
      <email>aching@coh.org</email>
    </contact>
    <investigator>
      <last_name>Jana Portnow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center (UCSD)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Nguyen</last_name>
      <phone>858-822-0201</phone>
      <email>anguyen85@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Wilson, NP</last_name>
      <phone>323-865-3945</phone>
      <email>lydia.wilson@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas C. Chen, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Robischon, RN</last_name>
      <phone>727-848-0661</phone>
      <email>Monica.robischon@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas E Ney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mollie R Geismer, RN, PhD</last_name>
      <phone>321-841-5206</phone>
      <email>Mollie.Geismer@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas G. Avgeropoulos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Smith, CCRP</last_name>
      <phone>813-745-3951</phone>
      <email>pam.smith@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Nam D Tran, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna &quot;Kasia&quot; Kopcewicz, CCRC</last_name>
      <phone>404-778-2981</phone>
      <email>kkopcew@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Willam Read, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago (UIC)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena M Yoder, Pharm. D</last_name>
      <phone>312-996-9240</phone>
      <email>hyoder@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert H. Engelhard, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Villano, MD, PhD</last_name>
      <phone>859-257-3379</phone>
      <email>jlvillano@uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tonya Gardner, CRC</last_name>
      <phone>(859) 323-0532</phone>
      <email>tonya.gardner@uky.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Villano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josiana Limones-Isenor, M.A. B.S.</last_name>
      <phone>502-629-3449</phone>
      <email>josiana.limones-isenor@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Renato V. LaRocca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Cushing, R.N.</last_name>
      <phone>207-885-4438</phone>
      <email>cushid@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Rajiv Desai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Zhen</last_name>
      <phone>410-502-4081</phone>
      <email>Szhen1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Alessandro Olivi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janlyn Murphy</last_name>
      <phone>617-667-1665</phone>
      <email>jmurphy7@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Eric T. Wong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Jensen, RN, BSN</last_name>
      <phone>617-636-5558</phone>
      <email>jjensen@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Lynne Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Gould</last_name>
      <phone>781-744-3956</phone>
      <email>Christine.A.Gould@lahey.org</email>
    </contact>
    <investigator>
      <last_name>Carlos A. David, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Winters, R.N.</last_name>
      <phone>313-916-1049</phone>
      <email>kwinter1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Tobias Walbert, MD PhD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Division of Oncology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Gwinn</last_name>
      <phone>314-747-4678</phone>
      <email>AGwinn@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>David D. Tran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Jersey Neuroscience Center - JFK Medical Center</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08818</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Porbeni</last_name>
      <phone>732-321-7000</phone>
      <phone_ext>68897</phone_ext>
      <email>cporbeni@jfkhealth.org</email>
    </contact>
    <investigator>
      <last_name>Joseph C. Landolfi, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Cappello, RN,BSN</last_name>
      <phone>551-996-5098</phone>
      <email>LCappello@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Samuel Goldlust, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa D Ricketts</last_name>
      <phone>212-746-7373</phone>
      <email>mdr2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Pannullo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center, Department of Neurosurgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Hum, M.S.</last_name>
      <phone>212-824-7312</phone>
      <email>Jean.Hum@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Isabelle M. Germano, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Smolenski, RN BSN OCN</last_name>
      <phone>216-445-1067</phone>
      <email>smolenk2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Gene Barnett, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Arthur G. James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danette Birkhimer, MS, RN, OCN, CNS</last_name>
      <phone>614-293-2897</phone>
      <email>danette.birkhimer@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jill Brown</last_name>
      <phone>614-293-5554</phone>
      <email>Jill.brown@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Herbert Newton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Health System</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Whitmire, RN</last_name>
      <phone>570-214-9603</phone>
      <email>awhitmire@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Steven A. Toms, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Michel, BS, MS</last_name>
      <phone>215-615-4597</phone>
      <email>Bernard.Michel@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Brem, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie T Kerr, CCRP</last_name>
      <phone>215-829-6720</phone>
      <email>kerm@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>John Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Vargas-Jaffe</last_name>
      <phone>412-235-1320</phone>
      <email>vargasjaffema@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Frank S. Lieberman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Carter, A.S,CCRP</last_name>
      <phone>214-820-8685</phone>
      <email>Kristy.Carter@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Karen L. Fink, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-8808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Wu, RN, MSN, OCN,</last_name>
      <phone>214-633-1753</phone>
      <email>Jean.Wu@Utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Choe, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimbra Harris, CCRP</last_name>
      <phone>713-441-3834</phone>
      <email>KSHarris@tmhs.org</email>
    </contact>
    <investigator>
      <last_name>Pamela New, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston (UTHSC)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Burk, LVN, CCRC</last_name>
      <phone>713-704-2359</phone>
      <email>Stacy.burk@memorialhermann.org</email>
    </contact>
    <investigator>
      <last_name>Jay-Jiguang Zhu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David W Sun, MD</last_name>
      <phone>713-534-1300</phone>
      <email>sun.davidwei@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yvonne Kew, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott and White Healthcare</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eromata Ebwe</last_name>
      <phone>254-724-6885</phone>
      <email>ekbwe@sw.org</email>
    </contact>
    <investigator>
      <last_name>Ekokobe Fonkem, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Burk</last_name>
      <phone>713-704-2359</phone>
      <email>Stacy.burk@memorialhermann.org</email>
    </contact>
    <investigator>
      <last_name>Jay-Jiguang Zhu, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Chapman</last_name>
      <phone>434-243-9360</phone>
      <email>KC9ZY@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>David Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Wood</last_name>
      <phone>206-320-7115</phone>
      <email>becky.wood@swedish.org</email>
    </contact>
    <investigator>
      <last_name>John Henson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fereshteh Assadian</last_name>
      <phone>206-685-5597</phone>
      <email>fassadia@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Maciej M Mrugala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz Payer, Prof.</last_name>
      <phone>+43 (0) 316 385-80388</phone>
      <email>franz.payer@meduni-graz.at</email>
    </contact>
    <investigator>
      <last_name>Franz Payer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Marosi, MD</last_name>
      <phone>+43 1 40400 4421</phone>
      <email>christine.marosi@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christine Marosi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMZ-Süd/Kaiser-Franz-Josef-Spital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Grisold, MD</last_name>
      <phone>+43 1 60191 2008</phone>
      <email>wolfgang.grisold@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Grisold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Rich</last_name>
      <phone>403-521-3031</phone>
      <email>Debra.Rich@AlbertaHealthServices.ca</email>
    </contact>
    <investigator>
      <last_name>Jacob Easaw, MD, PhD, FRCP(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Lylyk</last_name>
      <phone>204-789-1199</phone>
      <email>Elizabeth.lylyk@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Marshall Pitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton,</city>
        <state>Ontario</state>
        <zip>L8V5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hal Hirte</last_name>
      <phone>905-387-9495</phone>
    </contact>
    <investigator>
      <last_name>Holger (Hal) Hirte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Sharpe</last_name>
      <phone>(613) 737-7700</phone>
      <phone_ext>73281</phone_ext>
      <email>hsharpe@toh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Garth Nicholas, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Notre-Dame Hospital (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4 M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Trudel</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>26906</phone_ext>
      <email>diane.dt.trudel.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>David Roberge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jad Alshami</last_name>
      <phone>(514) 398-5750</phone>
      <email>jad.al-shami@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Scott Owen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill - Gerald Bronfman Centre for Clinical Research in Oncology -</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Fournier, PhD, CCRP</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>6771</phone_ext>
      <email>bfournier@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Thierry Muanza, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(CHUS) Centre Hospitalier Universitaire de Sherbrooke, Service de Neurochirurgie</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anick Champoux</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12811</phone_ext>
      <email>achampoux.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>David Mathieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Sroubek, M.D.</last_name>
      <phone>+420 (25727) 3091</phone>
      <email>Jan.Sroubek@homolka.cz</email>
    </contact>
    <investigator>
      <last_name>Jan Sroubek, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Sud-Salouel</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Chauffert, MD</last_name>
      <phone>+33 3 22 45 54 99</phone>
      <email>chauffert.bruno@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Chauffert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Anne Poiron</last_name>
      <phone>+33 02 41 35 59 71</phone>
      <email>MAPoiron@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Menei, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint André Centre Hospitalier Universitaire (CHU) des Hôpitaux de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Le Gall, SC</last_name>
      <phone>+33 05 57 82 13 04</phone>
      <email>marie.le-gall@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Catry-Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Neurology Lyon - University Claude Bernard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Chami</last_name>
      <phone>+33 04 72 35 58 42</phone>
      <email>linda.chami@chu.lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Jerome Honnorat, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Group Hospitals Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Anemet</last_name>
      <phone>01 42 16 04 04</phone>
      <email>louise.anemet@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Taillibert, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire de Toulouse Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Alexandra Benouaich-Amiel, M.D.</last_name>
      <phone>+33 (0)5 61 77 22 71</phone>
      <email>benouaich-amiel.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandra Benouaich-Amiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Westphal, M.D.</last_name>
      <phone>+49 (40) 7410-5345 3</phone>
    </contact>
    <investigator>
      <last_name>Manfred Westphal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madlen Rädel</last_name>
      <phone>+49 (6221) 56 35871</phone>
      <email>madlen.raedel@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Wick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximillian Mehdorn, M.D, PhD.</last_name>
      <phone>0049 431 597 4800</phone>
      <email>mehdorn@nch.uni-kiel.de</email>
    </contact>
    <investigator>
      <last_name>Maximilian Mehdorn, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmit Ben Harosh</last_name>
      <phone>972 52 426 2245</phone>
      <email>carmitbh@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Andrew Kanner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliero-Universitaria - Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Scerrati, MD</last_name>
      <phone>+39 0715964578</phone>
      <email>m.scerrati@univpm.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Scerrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Lecco</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Salmaggi</last_name>
      <phone>0039 0341 489111</phone>
      <email>a.salmaggi@ospedale.lecco.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Salmaggi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C. Besta Neurological Institute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Gaviani, M.D.</last_name>
      <phone>0039 02 2394 2440</phone>
      <email>paola.gaviani@istituto-besta.it</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Silvani, M.D.</last_name>
      <phone>+39 (022394) 23051</phone>
      <email>Antonio.Silvani@istituto-besta.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Silvani, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foundation Hospital Greater Policlinico</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Caroli, M.D.</last_name>
      <phone>0039 02 55035528</phone>
      <email>man.caroli@tin.it</email>
    </contact>
    <investigator>
      <last_name>Manuela Caroli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituti Fisioterapici Ospitalieri - Istituto Nazionale dei Tumori Regina Elena</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmine Carapella, M.D.</last_name>
      <phone>+39 06 52665595</phone>
      <email>carapella@ifo.it</email>
    </contact>
    <investigator>
      <last_name>Carmine Carapella, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Asan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji-Young Suh</last_name>
      <phone>+82-2-3010-7364</phone>
      <email>jysuh@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Se Hyuk Kim, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo-Nam Seo</last_name>
      <phone>+82-53-624-8354</phone>
    </contact>
    <investigator>
      <last_name>Oh Lyong Kim, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital (CNUH)</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Young Lee</last_name>
      <phone>+82-42-280-7399</phone>
      <email>ljy99@cnuh.co.kr</email>
    </contact>
    <investigator>
      <last_name>Hwan Jung Yun, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital (SNUH)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi-Yeon Yoo</last_name>
      <phone>+82-2-2072-3993</phone>
    </contact>
    <investigator>
      <last_name>Sun Ha Peak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital (YUHS)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyunsim Park</last_name>
      <phone>+82 2 2227 7867</phone>
    </contact>
    <investigator>
      <last_name>Jong-Hee Chang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital (CMC Seoul)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun-Mi Hyun</last_name>
      <phone>+82 2 2258 3054</phone>
    </contact>
    <investigator>
      <last_name>Yong Kil Hong, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital (SNUBH)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-jin Choi</last_name>
      <phone>+82-31-787-6001</phone>
      <email>r0415@snubh.org</email>
    </contact>
    <investigator>
      <last_name>Chae Yong Kim, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center (SMC)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangok Park</last_name>
      <phone>+82 2 3410 0867</phone>
      <email>sangok8133.park@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Dohyun Nam, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital (AUH)</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joolee Park</last_name>
      <phone>+82-31-219-4266</phone>
    </contact>
    <investigator>
      <last_name>Se Hyuk Kim, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Villa Freixa, MD</last_name>
      <phone>+34 93 497 88 05</phone>
      <email>svilla@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Salvador Villa Freixa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge-ICO Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Bruna Escuer, MD, PhD</last_name>
      <phone>+34 93 2607711</phone>
      <email>35078jbe@comb.cat</email>
    </contact>
    <investigator>
      <last_name>Jordi Bruna Escuer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Vilella, SC</last_name>
      <phone>+34 93 227 54 00</phone>
      <phone_ext>2811</phone_ext>
      <email>vilella@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Francesc Graus Graus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Martínez García, MD</last_name>
      <phone>'+34 93 248 38 62</phone>
      <email>MariaMartinezGarcia@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>María Martínez García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Perez Segura, MD</last_name>
      <phone>+34 91330364</phone>
      <email>perezsegura09@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pedro Perez Segura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria de los Angeles Vaz, MD</last_name>
      <phone>+34 91 336 82 63</phone>
      <email>avaz3@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Maria de los Angeles Vaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre, Servicio de Oncología Médica</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. J.M. Sepulveda, MD</last_name>
      <phone>+34 91 390 80 03</phone>
    </contact>
    <investigator>
      <last_name>Dr. J.M. Sepúlveda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenes Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose de Campos, MD</last_name>
      <phone>+34 659 574 378</phone>
      <email>JMcampos@fjd.es</email>
    </contact>
    <investigator>
      <last_name>Jose de Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Gallego Perez-Larraya, MD</last_name>
      <phone>+34 948 25 54 00</phone>
      <email>jgallego@unav.es</email>
    </contact>
    <investigator>
      <last_name>Jaime Gallego Perez-Larraya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institute</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Stragliotto, MD</last_name>
      <phone>+46 (0)8-517 72072</phone>
      <email>giuseppe.stragliotto@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Stragliotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Elsig</last_name>
      <phone>+(41) 21 3149709</phone>
      <email>Valerie.Elsig@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Roger Stupp, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Verena Reichl</last_name>
      <phone>+41 44 255 5511</phone>
      <email>verena.reichl@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Weller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95.</citation>
    <PMID>15126372</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5.</citation>
    <PMID>17551011</PMID>
  </reference>
  <reference>
    <citation>Salzberg M, Kirson E, Palti Y, Rochlitz C. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie. 2008 Jul;31(7):362-5. Epub 2008 Jun 24.</citation>
    <PMID>18596382</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009 Apr 23; [Epub ahead of print]</citation>
    <PMID>19387848</PMID>
  </reference>
  <reference>
    <citation>Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A, Mordechovich D, Gurvich Z, Shmueli E, Goldsher D, Wasserman Y, Palti Y. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009 Jan 8;9:1.</citation>
    <PMID>19133110</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 21, 2013</lastchanged_date>
  <firstreceived_date>June 5, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>GBM</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Treatment</keyword>
  <keyword>Minimal toxicity</keyword>
  <keyword>Newly Diagnosed</keyword>
  <keyword>TTFields</keyword>
  <keyword>Tumor Treating Fields</keyword>
  <keyword>NovoCure</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
